SILVER SPRING, Md., Feb. 14, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for the treatment of human diseases, announced today its subsidiary, Medical Marijuana Sciences, Inc., is focusing on developing treatments for brain cancers, including glioblastoma multiforme, that are based on cannabinoids . Over the past few years, a significant amount of data in the scientific literature has indicated that cannabinoids, including Delta-9-tetrahydrocannabinol(THC) and cannabidiol (CBD), can inhibit the growth of brain cancer cells in the laboratory and in animals. Recent evidence points to their potential value when used in the treatment of glioblastoma multiforme. In a pilot clinical study in which patients with glioblastoma multiforme were treated with "safe" levels of THC, the median survival of patients was 24 weeks, equaling that of the "benchmark" drug (temozolomide) at that time. According to American Cancer Society estimates, about 23,000 people will be diagnosed with malignant brain and spinal cord tumors in 2013 and about 14,000 people will die from them in the US alone. At present, no recommended tests are available to screen for brain tumors and many of these tumors are only detected when symptoms of their presence manifest themselves. Glioblastoma multiforme spreads easily throughout brain tissue making it difficult to remove surgically. Other options for its treatment include radiation therapy and chemotherapy. Only about 10 cancer drugs have been used to treat such brain tumors. Given the "life expectancy" statistics noted above, it is apparent that new drugs and new treatment options for brain tumors, such as glioblastoma multiforme, are urgently needed. Dr. Gerald Crabtree, Nuvilex's COO commented, "Because of the information already available regarding the use of cannabinoids against glioblastoma multiforme, we believe that this class of therapeutic molecules will enable us to advance new treatments for this form of brain cancer." About Nuvilex Nuvilex, Inc. (OTCQB:NVLX) has been a provider of all-natural products for many years. The company has been expanded to increase its natural product-based footprint through medical marijuana studies. We are an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for research and medicine. New developments by our company and subsidiaries will be substantial as we have been working on many fronts to move us forward. Our company's offerings will ultimately include cancer, diabetes and other treatments using the Company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494 Safe Harbor Statement This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.
CONTACT: Investor Relations Contact: Marlin Molinaro Marmel Communications, LLC Ph: (702) 434-8692 firstname.lastname@example.org